Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Harnessing extracellular vesicles from adipose-derived stem cells for the treatment of 4-vinylcyclohexene diepoxide-induced premature ovarian insufficiency.

Li Y., Chen F., Zhao W., Sun D., Zhang L., Qiao R.

Animal Study on Hair & Scalp, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40765000
PMCID
PMC12326641
DOI
10.1186/s13287-025-04553-6
Citations
2

Abstract (original English)

Background Premature ovarian insufficiency (POI) is a challenging condition with limited effective treatments. Adipose-derived stem cells (ADSCs) have demonstrated potential in tissue repair, and their extracellular vesicles (ADSC-EVs) show more safety in clinical translation. However, the role and mechanism of ADSC-EVs in the treatment of POI are not yet fully understood. This study aims to investigate the protective effects of ADSC-EVs on rat POI models induced by 4-vinylcyclohexene diepoxide (VCD) and to explore the potential therapeutic mechanisms. Methods Rat ADSCs and ADSC-EVs were isolated and characterized. The POI rat model was established via intraperitoneal injection of VCD for 15 consecutive days. ADSCs and ADSC-EVs were injected into the ovaries for treatment. Ovary function was assessed by monitoring estrous cycles, follicle counts, sexual hormone levels, and ovulation. Molecular mechanisms were investigated using TUNEL staining, immunohistochemistry, quantitative polymerase chain reaction, and western blotting. In vitro, primary rat granulosa cells were treated with VCD in the presence or absence of ADSC-EVs. Cell proliferative ability, hormone secretion, apoptosis rate, and relative molecular expression were measured. Whole-transcriptome sequencing and DIA proteomics of ADSC-EVs were performed to identify bioactive molecules. Results ADSC-EVs protected granulosa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsFemalePrimary Ovarian InsufficiencyRatsCyclohexenesExtracellular VesiclesVinyl CompoundsRats, Sprague-DawleyStem CellsEpoxy Compounds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research